Bildkälla: Stockfoto

InDex Pharmaceuticals: USD50m deal with Viatris - Redeye

Redeye endorses yesterday evenings news that InDex Pharmaceuticals have entered into a USD50m licensing agreement with Viatris Japan to develop and commercialize cobitolimod in Japan. We leave our initial comments.

Redeye endorses yesterday evenings news that InDex Pharmaceuticals have entered into a USD50m licensing agreement with Viatris Japan to develop and commercialize cobitolimod in Japan. We leave our initial comments.
Börsvärldens nyhetsbrev
ANNONSER